The current study is the first study performing mutation analyses in BRCA1, BRCA2 and PALB2 and determining the frequency of CHEK2 c.1100delC in triple negative and/or premenopausal breast cancer patients in South Africa through both next generation sequencing and large rearrangement testing. Here, CHEK2 is linked to breast cancer.